Home › NDC Lookup › RxCUI directory › RxCUI 1547118

Suvorexant 20 MG Oral Tablet [Belsomra] — RxCUI 1547118

RxNorm drug concept · Semantic branded drug
RxCUI 1547118 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1547118
Official nameSuvorexant 20 MG Oral Tablet [Belsomra]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asBelsomra 20 MG Oral Tablet
FDA products mapped4
Package NDCs mapped8
Reported Medicaid activity (SDUD)49,093 prescriptions · 49 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Suvorexant: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Belsomra works by blocking specific brain chemicals called orexins that keep you awake. Most older sleep medications broadly sedate the entire brain, but Belsomra targets the wake-...
  • What exactly does Belsomra do, and how is it different from other sleep aids?
  • Belsomra is intended for once-nightly use, and you should only take it when you have at least 7 full hours to sleep before you need to be up. It typically starts working within abo...
  • Can I take Belsomra every night, and how long does it take to work?
📖 Read our full Suvorexant guide →

🕸️ Concept Web — How Suvorexant 20 MG Oral Tablet [Belsomra] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Suvorexant 20 MG Oral Tablet [Belsomra] RxCUI 1547118

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Suvorexant 1547099
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Belsomra 1547105
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Suvorexant Oral Tablet 1547103
    • Suvorexant Oral Product 1547101
    • Suvorexant Pill 1547102
    • Suvorexant Oral Tablet [Belsomra] 1547107
    • Belsomra Oral Product 1547108
    • Belsomra Pill 1547109
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Suvorexant 20 MG Oral Tablet SCD · 1547116
  • Suvorexant 20 MG SCDC · 1547115
  • Suvorexant Oral Tablet SCDF · 1547103
  • Suvorexant Oral Product SCDG · 1547101
  • Suvorexant Pill SCDG · 1547102

Brand-Name Concepts

  • Suvorexant 20 MG [Belsomra] SBDC · 1547117
  • Suvorexant Oral Tablet [Belsomra] SBDF · 1547107
  • Belsomra Oral Product SBDG · 1547108
  • Belsomra Pill SBDG · 1547109
  • Belsomra BN · 1547105

📦 FDA Products & Package NDCs

4 products · 8 package NDCs
8 package NDCs map to RxCUI 1547118 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00006-0005-13 1 BLISTER PACK in 1 CASE (0006-0005-13) / 3 TABLET, FILM CO... BELSOMRA Merck Sharp & Dohme LLC 2014-08-29
00006-0005-30 3 CASE in 1 CARTON (0006-0005-30) / 1 BLISTER PACK in 1 CAS... BELSOMRA Merck Sharp & Dohme LLC 2014-08-29
00006-0033-13 1 BLISTER PACK in 1 CASE (0006-0033-13) / 3 TABLET, FILM CO... BELSOMRA Merck Sharp & Dohme LLC 2014-08-29
00006-0033-30 3 CASE in 1 CARTON (0006-0033-30) / 1 BLISTER PACK in 1 CAS... BELSOMRA Merck Sharp & Dohme LLC 2014-08-29
00006-0325-13 1 BLISTER PACK in 1 CASE (0006-0325-13) / 3 TABLET, FILM CO... BELSOMRA Merck Sharp & Dohme LLC 2014-08-29
00006-0325-30 3 CASE in 1 CARTON (0006-0325-30) / 1 BLISTER PACK in 1 CAS... BELSOMRA Merck Sharp & Dohme LLC 2014-08-29
00006-0335-13 1 BLISTER PACK in 1 CASE (0006-0335-13) / 3 TABLET, FILM CO... BELSOMRA Merck Sharp & Dohme LLC 2014-08-29
00006-0335-30 3 CASE in 1 CARTON (0006-0335-30) / 1 BLISTER PACK in 1 CAS... BELSOMRA Merck Sharp & Dohme LLC 2014-08-29
Observed labelers: Merck Sharp & Dohme LLC (8) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.